{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:21:57Z","timestamp":1791292917898,"version":"4.1.0"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:p>Patient acceptance of long-acting injectable antiretroviral (LAI-ARV) HIV-1 regimens will determine uptake. Although previous literature reports high satisfaction, these data stem from clinical trials subject to selection bias. This cross-sectional survey from the HIV practices of an urban academic medical center assessed perceptions and preferences using Likert scales toward overall acceptability, proposed frequencies, injection-site reaction durations, and distribution venue. 59% of surveys were completed resulting 202 respondents. 60% were male, 72% black, and the median age was 49 (IQR 36-58). 93% reported a once daily tablet frequency, 69% reported single tablet regimens, and 59% reported missing zero doses in the prior 30 days. Patients self-categorized as likely (57%) or unlikely (43%) to accept LAI-ARV. Both decreasing frequencies between injections and durations of injection-site reactions resulted higher acceptability scores. 57% of respondents preferred receiving an injectable from their clinician\u2019s office over other potential options. These data demonstrate positive LAI-ARV acceptance potential.<\/jats:p>","DOI":"10.1177\/2325958220981265","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T11:45:49Z","timestamp":1608205549000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-9893","authenticated-orcid":false,"given":"David E.","family":"Koren","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodymyra","family":"Fedkiv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geena","family":"Kludjian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Temple University Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Bettiker","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Tedaldi","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Samuel","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"bibr1-2325958220981265","unstructured":"The Joint United Nations Programme on HIV\/AIDS. 90\u201390-90 An ambitious treatment target to help end the AIDS epidemic. 2014. Accessed December 6, 2019. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/90-90-90_en.pdf"},{"key":"bibr2-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"bibr3-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1080\/13548506.2014.945601"},{"key":"bibr4-2325958220981265","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565080-00007"},{"key":"bibr5-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000473"},{"key":"bibr6-2325958220981265","unstructured":"Healthcare V. ViiV healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting regimen for the treatment of HIV. Accessed June 1, 2020."},{"key":"bibr7-2325958220981265","volume-title":"Presentation at Conference on Retroviruses and Opportunistic Infections","author":"Sager JE"},{"key":"bibr8-2325958220981265","volume-title":"Presentation at Conference on Retroviruses and Opportunistic Infections","author":"Dhody K"},{"key":"bibr9-2325958220981265","unstructured":"ViiV Healthcare. Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in human-immunodeficiency virus-1 (HIV-1) infected adults. Accessed December 6, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03299049.NLMidentifier:NCT03299049"},{"key":"bibr10-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000599"},{"key":"bibr11-2325958220981265","unstructured":"Cohen C, Green J, Wintfeld N, Patel K. Fuzeon: Patient acceptance with self-injection of enfuvirtide (Fuzeon) for HIV over 48 of treatment Presentation at 9th European AIDS Conference, October 25-29, 2003. Warsaw, Poland (Abstract 7.1\/1)."},{"key":"bibr12-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1310\/hct0902-83"},{"key":"bibr13-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"bibr14-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"},{"key":"bibr15-2325958220981265","volume-title":"Presentation at 10th IAS Conference on HIV Science","author":"Murray M"},{"key":"bibr16-2325958220981265","volume-title":"Presentation at 10th IAS Conference on HIV Science","author":"Murray M"},{"key":"bibr17-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000564"},{"key":"bibr18-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj069"},{"key":"bibr19-2325958220981265","author":"Simoni JM","year":"2019","journal-title":"AIDS Behav"},{"key":"bibr20-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2018.0198"},{"key":"bibr21-2325958220981265","volume-title":"Presentation at IDWeek 2019","author":"Garris C"},{"key":"bibr22-2325958220981265","volume-title":"Presentation at 17th European AIDS Conference","author":"Khuong-Josses MA"},{"key":"bibr23-2325958220981265","unstructured":"Anglia UoE. Medication Acceptability Questionnaire (MAQ). Accessed June 1, 2020. https:\/\/www.uea.ac.uk\/pharmacy\/research\/maq"},{"key":"bibr24-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr25-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000158"},{"key":"bibr26-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/69.22.2002"},{"key":"bibr27-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000842"},{"key":"bibr28-2325958220981265","doi-asserted-by":"publisher","DOI":"10.1310\/hct1501-14"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2325958220981265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2325958220981265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2325958220981265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:49:53Z","timestamp":1777502993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2325958220981265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":28,"alternative-id":["10.1177\/2325958220981265"],"URL":"https:\/\/doi.org\/10.1177\/2325958220981265","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"article-number":"2325958220981265"}}